Navigation Links
Resistant wheat rebuilds cell walls when attacked by Hessian flies
Date:5/19/2010

thought to be responsible for cutin and wax production was affected by the fly larvae.

Nemacheck said real-time polymerase chain reactions were used to quantify gene expression. The process uses an enzyme and other reagents to amplify target sequences from the gene of interest to levels that are detectable in order to determine the levels of messenger RNA in the tissue samples. Comparing the amount of messenger RNA in different plant samples is important because messenger RNA carries instructions that tell cells which proteins to produce, such as those responsible for generating cutin or wax. Less messenger RNA in the original tissue samples would indicate lower levels of gene expression, which ultimately determines cutin or wax production.

"The change in gene expression reflected what we observed," Nemacheck said. "In resistant plants, expression of the genes that control wax and cutin production was increased. Susceptible plants had a decrease in the expression of those genes."

Plants were determined to have become permeable through staining the tissue with a red dye that was placed on the larvae feeding sites. Resistant plants that were observed to have increased cutin production had slight red spotting along the leaves from the dye. But those that were susceptible absorbed the dye because cutin was lacking and the dye was able to seep into the plant's cells.


'/>"/>

Contact: Brian Wallheimer
bwallhei@purdue.edu
765-496-2050
Purdue University
Source:Eurekalert

Page: 1 2

Related biology news :

1. NIH grants K-State researcher nearly $1.5 million to study antibiotic-resistant bacteria
2. NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating
3. Resistant wheat goes for the gut to protect against Hessian flies
4. ARS researchers develop method to speed up breeding of scab-resistant barley cultivars
5. Drug-resistant urinary tract infections spreading worldwide
6. Research yields new agent for some drug-resistant non-small cell lung cancers
7. Novel nanotechnology heals abscesses caused by resistant staph bacteria
8. Experts: Disease-resistant plants enhance profits, client satisfaction
9. VAI researchers find long awaited key to creating drought resistant crops
10. First metallic nanoparticles resistant to extreme heat
11. Rot-resistant wheat could save farmers millions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... of the European corn borer has saved Midwest farmers billions ... in Science . Research conducted by several Midwest ... billion for corn growers in Illinois, Minnesota, and Wisconsin over ... this total benefiting non-Bt corn growers. Comparable estimates for Iowa ...
... Conn.A team of Yale University scientists has engineered the ... into incorporating foreign small molecules and embedding them within ... the journal ACS Chemical Biology this week, ... wall of a pathogenic "Gram-positive" bacteriaorganisms responsible not only ...
... States seeks to lessen its reliance on foreign oil, ... the National Renewable Energy Laboratory, a branch of the ... and could someday supply 3 percent to 5 percent ... to achieving that goal is figuring how to efficiently ...
Cached Biology News:Transgenic corn suppresses European corn borer, saves farmers billions 2Scientists trick bacteria with small molecules 2Brown University chemists simplify biodiesel conversion 2Brown University chemists simplify biodiesel conversion 3
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... 2015 Launched by the ... in December 2011, ,SARAH, - the French ... versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled ... SARAH, a large French study of patients ... HCC) has completed patient enrolment, exceeding its 400-patient target, ...
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Md., Dec. 5 Micromet, Inc. (Nasdaq:,MITI), a ... antibody-based products for cancer, inflammation and autoimmune,diseases, today ... Officer of Micromet, will be part of a ... Therapies For Cancer" at the 2007,RBC Capital Markets ...
... $8.1 Million Financing in Connection ... Reverse Stock Split Planned for January 2008, ... today announced that the Company has:, - Signed an agreement ... based in Israel. The acquisition,is expected to close tomorrow. The initial ...
... (AMEX: IMM ) announced today that the ... SA (Euronext Paris - ticker code BIO) to,commercialize ... the treatment of pneumocystis pneumonia (PCP) in AIDS ... also known as,African sleeping sickness. Pafuramidine is currently ...
Cached Biology Technology:Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 2Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 3Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 4
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Normal serum collected from healthy Kunming mice....
Biology Products: